Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay
Vela Diagnostics announced that its Sentosa® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) starting January 2022.
January 10, 2022
by prnasia
Vela Diagnostics expands automation options for SARS-CoV-2 RT-PCR Test
Vela Diagnostics announced today that the ViroKey® SARS-CoV-2 RT-PCR Test v2.0 that received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA)...
November 22, 2021
by prnasia
Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy
Vela Diagnostics announced a collaboration with the National Cancer Centre of Singapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) ...
June 4, 2021
by prnasia
Vela Diagnostics adds two SARS-CoV-2 assays for virus genotyping, and variant identification to its COVID-19 testing solutions
Vela Diagnostics announced that it has added ViroKey™ SQ FLEX SARS-CoV-2 Genotyping Assay and ViroKey™ SARS-CoV-2 ID RT-PCR Test to its portfolio offering.
February 26, 2021
by prnasia
SARS-CoV-2 RT-PCR Test v2.0 Granted Authorized for Emergency Use in US
Vela Diagnostics announced the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 has obtained the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
September 30, 2020
by americanpharmaceuticalreview
Vela Diagnostics' SARS-CoV-2 RT-PCR Test v2.0 Authorized for Emergency Use in the U.S.
Vela Diagnostics announced today that the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 has obtained the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
September 23, 2020
by prnasia
FDA issues Emergency Use Authorization to Vela Diagnostics' Coronavirus PCR Test
Vela Diagnostics announced the manual version of its coronavirus PCR test has obtained Emergency Use Authorization from the U.S. Food and Drug Administration (FDA).
August 12, 2020
by americanpharmaceuticalreview
Vela Diagnostics receives CE-IVD approval and Provisional Authorisation from the Health Sciences Authority in Singapore for automated COVID-19 detection test
Vela Diagnostics announced today that an automated version of its COVID-19 detection test, the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0, has received the CE mark for in vitro diagnostic use as well as Provisional Authorisation from the Health Sciences Authori
July 13, 2020
by prnasia